<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523885</url>
  </required_header>
  <id_info>
    <org_study_id>HLM_JDR3</org_study_id>
    <nct_id>NCT02523885</nct_id>
  </id_info>
  <brief_title>Use of Non Steroidal Antiinflammatory Drugs in Patients With Community Acquired Pneumonia</brief_title>
  <acronym>ALPAJ</acronym>
  <official_title>Descriptive Analysis of Non Steroidal Antiinflammatory Drugs Use in Patients Diagnosed With Community Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Louis Mourier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Louis Mourier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate exposure to nonsteroidal antiinflammatory drugs (NSAIDs) during outpatient
      management at the early stage of community-acquired pneumonia (CAP) requiring hospital
      consultation. Non-interventional observational study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent data suggests that such exposure to NSAIDs is associated with delay in CAP diagnosis
      and antibiotic prescription that influence CAP presention and outcome. The investigators'
      working hypothesis is that NSAIDs use may mask initial symptoms and delay antimicrobial
      therapy, thus predisposing to worse outcomes. All patients presenting at one of the three
      following locations (emergency department, ICU or pneumology ward) with a suspicion of
      community-acquired pneumonia will be screened for eligibility. Exposure or not to NSAIDs will
      be investigated. Clinical, biological and radioloigcal features and outcome of CAP will be
      compared with respect to NSAIDs exposure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>binary composite primary endpoint</measure>
    <time_frame>28 days</time_frame>
    <description>presence or absence of one or more of the following : occurrence of at least one pneumonia-related complication; need for ICU admission; prolonged length of hospital stay.
pneumonia-related complications include: worsening of hypoxemia; need for mechanical ventilation; occurrence or increase of pleural effusion; empyema; occurrence of septic shock;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pneumonia severity index</measure>
    <time_frame>2 days</time_frame>
    <description>the pneumonia severity index calculated at inclusion will be compared in exposed and non-exposed to NSAID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CURB score at inclusion</measure>
    <time_frame>2 days</time_frame>
    <description>the CURB score (confusion, blood urea nitrogen, respiratory rate and systolic blood pressure) at inclusion will be compared in exposed and non-exposed to NSAID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of antimicrobial therapy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurence of a nosocomial infection</measure>
    <time_frame>28 days</time_frame>
    <description>occurrence of nosocomial infections (including nosocomial pneumonia, catheter-related blood stream infection, and urinary tract nosocomial infection) will be compared in exposed and non-exposed to NSAID patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>chest pain</measure>
    <time_frame>2 days</time_frame>
    <description>presence or absence of chest pain at inclusion will compared between exposed and non-exposed to NSAID patients</description>
  </other_outcome>
  <enrollment type="Actual">181</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all adult patient presenting either to the emergency department or admitted directly to the
        ICU or the pneumology ward with a suspicion of CAP will be screened
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: at least two among the following signs

          -  temperature &gt; 37.8 °C

          -  respiratory rate &gt; 25/min

          -  heat rate &gt; 100/min

          -  cough

          -  expectoration

          -  chest pain

          -  crackles upon lung auscultation

        and new infiltrate on the chest x-ray

        Exclusion Criteria:

          -  ongoing pregnancy

          -  sickle cell disease

          -  tracheostomy

          -  long term oxygen therapy

          -  cystic fibrosis or bronchiectasis

          -  neutropenia (&lt; 500 cells/mm3)

          -  ongoing solid or hematologic cancer or anticancerous chemotherapy

          -  HIV infection

          -  liver cirrhosis

          -  long term corticosteroid treatment (20mg per day equivalent prednisone for more than
             15 days)

          -  preexisting treatment with NSAIDs for more than 15 days

          -  hospital admission for more than 48hours

          -  aspiration pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Damien RICARD, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asssistance Pulique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muriel FARTOUKH, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan MESSIKA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillaume Voiriot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Hajage, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Mourier Hospital</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Max Fourestier</name>
      <address>
        <city>Nanterre</city>
        <zip>92000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenon Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Voiriot G, Dury S, Parrot A, Mayaud C, Fartoukh M. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest. 2011 Feb;139(2):387-394. doi: 10.1378/chest.09-3102. Epub 2010 Aug 19.</citation>
    <PMID>20724739</PMID>
  </reference>
  <reference>
    <citation>Messika J, Sztrymf B, Bertrand F, Billard-Pomares T, Barnaud G, Branger C, Dreyfuss D, Ricard JD. Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients. J Crit Care. 2014 Oct;29(5):733-8. doi: 10.1016/j.jcrc.2014.05.021. Epub 2014 Jun 4. Review.</citation>
    <PMID>24997726</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Louis Mourier</investigator_affiliation>
    <investigator_full_name>Prof Jean-Damien RICARD</investigator_full_name>
    <investigator_title>Professor of Intensive Care Medicine, assistant head of ICU</investigator_title>
  </responsible_party>
  <keyword>Pneumonia, Bacterial [C01.252.620]</keyword>
  <keyword>Bronchopneumonia [C08.381.677.127]</keyword>
  <keyword>Pleuropneumonia [C08.730.610.473]</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

